Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Zenas BioPharma (ZBIO) Cash from Investing Activities (2024 - 2025)

Zenas BioPharma has reported Cash from Investing Activities over the past 2 years, most recently at -$93.4 million for Q4 2025.

Quarterly results put Cash from Investing Activities at -$93.4 million for Q4 2025, down 2399.71% from a year ago — trailing twelve months through Dec 2025 was -$251.9 million (down 724.45% YoY), and the annual figure for FY2025 was -$251.9 million, down 724.45%.
Cash from Investing Activities for Q4 2025 was -$93.4 million at Zenas BioPharma, down from $40.0 million in the prior quarter.
Over the last five years, Cash from Investing Activities for ZBIO hit a ceiling of $40.0 million in Q3 2025 and a floor of -$112.3 million in Q2 2025.